What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)

被引:5
|
作者
Vardar, Rukiye [1 ]
Keskin, Muharrem [2 ]
机构
[1] Ege Univ, Dept Gastroenterol, Sch Med, Izmir, Turkey
[2] Necmettin Erbakan Univ, Dept Gastroenterol, Sch Med, Konya, Turkey
关键词
Empirical PPI test; GERD; PPI trial test; NONCARDIAC CHEST-PAIN; HIGH-DOSE RABEPRAZOLE; OMEPRAZOLE TEST; PRIMARY-CARE; NEGATIVE PATIENTS; SYMPTOM RESPONSE; CROSSOVER TRIAL; DOUBLE-BLIND; LANSOPRAZOLE; ENDOSCOPY;
D O I
10.5152/tjg.2017.05
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Empirical acid suppression tests that are performed with proton pump inhibitors (PPI) are used to detect both the presence of acid-related gastrointestinal symptoms and gastroesophageal reflux disease (GERD). In comparison to other diagnostic methods, it is non-invasive, easily applicable, and cost-effective in the diagnosis of GERD. In addition to typical reflux symptoms, it can also be used for diagnostic purposes in patients with non-cardiac chest pain (NCCP). If the symptom response is 50% and above when obtained using the PPI test in patients with NCCP, it can be considered as positive and the treatment should be continued sensitivity of the PPI test in patients with typical symptoms of GERD is 27%-89%, while its specificity is 35%-83%. Although there are differences related to the duration and dosage of the PPI test, a significant difference has not been found according to the type of PPI. When PPI test sensitivity and specificity were calculated by cumulatively evaluating the data regarding the PPI test in the literature, a sensitivity of 82.3% and specificity of 51.5% was obtained. It has been found that high doses of PPI were mostly used in studies, and the duration of the median test was 14 days. As a result, the sensitivity of PPI trial test is good, but the specificity is low in the diagnosis of GERD in patients with typical reflux symptoms.
引用
收藏
页码:S12 / S15
页数:4
相关论文
共 50 条
  • [21] Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy
    Sugimoto, Mitsushige
    Nishino, Masafumi
    Kodaira, Chise
    Yamade, Mihoko
    Uotani, Takahiro
    Ikuma, Mutsuhiro
    Umemura, Kazuo
    Furuta, Takahisa
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (14) : 1858 - 1865
  • [22] Proton Pump Inhibitor Prescriptions and Subsequent Use in US Veterans Diagnosed with Gastroesophageal Reflux Disease
    Andrew J. Gawron
    John E. Pandolfino
    Scott Miskevics
    Sherri L. LaVela
    Journal of General Internal Medicine, 2013, 28 : 930 - 937
  • [23] Esophageal Mucosal Breaks in Gastroesophageal Reflux Disease Partially Responsive to Proton Pump Inhibitor Therapy
    Shaheen, Nicholas J.
    Denison, Hans
    Bjorck, Karin
    Silberg, Debra G.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (04) : 529 - 534
  • [24] Proton Pump Inhibitor Prescriptions and Subsequent Use in US Veterans Diagnosed with Gastroesophageal Reflux Disease
    Gawron, Andrew J.
    Pandolfino, John E.
    Miskevics, Scott
    LaVela, Sherri L.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 (07) : 930 - 937
  • [25] Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease
    Gotoh, Yasuhiko
    Ishibashi, Emiko
    Honda, Shunichiro
    Nakaya, Tomohisa
    Noguchi, Chishio
    Kagawa, Koichi
    Murakami, Kazunari
    MEDICINE, 2020, 99 (11) : E19520
  • [26] Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe
    Gyawali C.P.
    Current Gastroenterology Reports, 2017, 19 (9)
  • [27] Comparing the efficacy of different proton pump inhibitor dosing regimens for the treatment of gastroesophageal reflux disease: a systematic review and meta-analysis
    Nguyen, Tyra
    Barnhill, Katherine
    Zhornitskiy, Alex
    Yu, Kyung Sang
    Fuller, Garth
    Makaroff, Katherine
    Spiegel, Brennan M. R.
    Gresham, Gillian
    Almario, Christopher, V
    DISEASES OF THE ESOPHAGUS, 2024, 38 (01)
  • [28] Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study
    de Bortoli, N.
    Guidi, G.
    Martinucci, I.
    Savarino, E.
    Imam, H.
    Bertani, L.
    Russo, S.
    Franchi, R.
    Macchia, L.
    Furnari, M.
    Ceccarelli, L.
    Savarino, V.
    Marchi, S.
    DISEASES OF THE ESOPHAGUS, 2016, 29 (02) : 197 - 204
  • [29] Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study
    Jonasson, Christian
    Tvete, Ingunn F.
    Hatlebakk, Jan G.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2013, 48 (09) : 1010 - 1017
  • [30] A novel endoscopic submucosal dissection technique for proton pump inhibitor-refractory gastroesophageal reflux disease
    Ota, Kazuhiro
    Takeuchi, Toshihisa
    Harada, Satoshi
    Edogawa, Shoko
    Kojima, Yuichi
    Inoue, Takuya
    Higuchi, Kazuhide
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2014, 49 (12) : 1409 - 1413